Compare Davita Inc (DVA) vs D Wave Quantum Inc (QBTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs D Wave Quantum Inc — how do they compare? Davita Inc trades at $230.35 (market cap $14.92B), while D Wave Quantum Inc trades at $18.97 (market cap $7.02B). The key difference: Davita Inc is far larger — about 2.1× D Wave Quantum Inc's market cap, and Davita Inc is trading nearer its 52-week high, D Wave Quantum Inc nearer its low. Which is the better fit depends on your goals.
| DVA | QBTS | |
|---|---|---|
Market Cap | $14.92B | $7.02B |
Sector | Health | Technology |
52-Week High | $235.71 | $44.78 |
52-Week Low | $103.87 | $12.98 |
Enterprise Value | $27.47B | $6.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $235.58, up 1.19% on the day, near its pivot point of $236. The stock shows a bullish technical trend with strong moving average signals, though RSI levels suggest potential overbought conditions. Fundamentally, revenue grew to $13.64B in 2025, but net income margin dipped to 5.65%. Recent earnings beat expectations in Q4 2025 and Q1 2026, while Q3 2025 missed. Analyst sentiment is mixed with a consensus price target of $231.80, slightly below the current price.
The outlook for DVA is cautiously optimistic, supported by steady revenue growth and expansion in kidney care services. Key risks include high debt levels, with debt-to-asset ratio rising to 65.55% in 2025, and margin pressure from rising costs. Investment opportunity lies in continued execution of value-based care programs and AI-driven efficiency gains, but investors should monitor debt management and regulatory changes in healthcare reimbursement.
QBTS trades at $18.67, down 7.05% today amid a broader quantum computing sector sell-off. The stock exhibits a bearish technical signal despite oversold RSI readings, while fundamentals reveal severe losses with a net income margin of -2,957.23% and negative cash flow from operations. Recent news highlights its Nasdaq listing transfer and IDC MarketScape recognition as a quantum computing leader.
Analyst consensus remains strongly bullish with a $39.86 price target, but the stock faces significant execution risks, cash burn, and intense competition. Investment appeal hinges on speculative growth in commercial quantum adoption, yet profitability remains distant, demanding high risk tolerance from investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About D Wave Quantum Inc
D-Wave Quantum Inc. is a global leader in the development and delivery of quantum computing systems, software, and services. The company specializes in annealing quantum computers designed to solve complex optimization problems across industries such as logistics, materials science, and financial modeling. D-Wave offers its technology through the cloud, allowing customers to build and run real-world quantum applications today, making it a key player in the commercialization of quantum computing.
Read more on QBTS →
